The primary endpoint of the randomized, double-blind, placebo-controlled trial is the effect of repeat oral dosing of the Cav2.2 selective blocker on the pain experienced in PHN after three weeks, compared with baseline

Addex Therapeutics SA, of Geneva, reported preclinical data showing that its mGlu5 negative allosteric modulator oral small molecule, dipraglurant, dose-dependently prevented the abnormal excitatory effect observed on brain slices of transgenic primary generalized torsion dystonia 1 (DYT1) mice overexpressing the human mutant TOR1A gene by decreasing the paradoxical neuronal activity induced by the dopamine D2 receptor agonist quinpirole. DYT1 is a common and severe genetic form of dystonia

The multinational, randomized, double-blind, placebo-controlled study reached the recruitment goal of 120 patients with treatment-refractory ulcerative colitis

Convergence Pharmaceuticals Ltd., of Cambridge, UK, reported interim data from the ongoing Phase II trial testing sodium channel blocker CNV1014802 in patients with trigeminal neuralgia, a severe form of facial pain, showing that, in the open-label portion, a total of 70 percent had a successful response and were subsequently randomized into the double-blind treatment period

Efficacy was demonstrated in a 52-week, placebo-controlled, double-blind, randomized-withdrawal, Phase III maintenance trial of Abilify Maintena in patients with schizophrenia

Efficacy was demonstrated in a 52-week, placebo-controlled, double-blind, randomized-withdrawal, Phase III maintenance trial of Abilify Maintena in patients with schizophrenia

The double-blind, parallel-group trials included 912 asthma patients randomized to additional tiotropium Respimat 5 mg or placebo for 48 weeks...The clinical trial is a randomized, double-blind, placebo-controlled parallel group study to evaluate the safety, clinical efficacy and pharmacokinetic profile of bertilimumab in subjects with active moderate-to-severe ulcerative colitis

The double-blind, parallel-group trials included 912 asthma patients randomized to additional tiotropium Respimat 5 mg or placebo for 48 weeks

The extension will enable the company to increase the number of centers involved in the randomized, double-blind trial

The randomized, double-blind, placebo-controlled CHEST-I (Chronic Thromboembolic Pulmonary Hypertension sGC-Stimulator Trial) assessed the efficacy and safety of oral riociguat in inoperable CTEPH or CTEPH that persisted or reoccurred after pulmonary endarterectomy...The randomized, double-blind, placebo-controlled PATENT-1 (Pulmonary Arterial Hypertension sGC-Stimulator Trial) assessed oral riociguat in treatment-naïve and pre-treated patients with symptomatic PAH

The randomized, double-blind, placebo-controlled study will assess efficacy and safety of two doses of Nefecon in 90 patients with primary IgA nephropathy who are at risk for end-stage renal disease

An open-label pilot phase will be followed by a three-arm, randomized, double-blind, placebo-controlled main phase comparing two different dose regimens of NOX-H94 with placebo

The applications are supported by findings from Phase III study Multicenter, Randomised, Double-blind, Placebo-controlled trials of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis (PSUMMIT I and PSUMMIT II), which evaluated the efficacy and safety of subcutaneously administered Stelara 45 mg or 90 mg at weeks 0, four and then every 12 weeks

The primary objective of the multicenter, randomized, double-blind, placebo-controlled study is to confirm the ability of ataluren to slow disease progression as assessed by ambulatory ability based on the 6MWD in patients with nmDMD

The primary endpoint of the double-blind study was safety and tolerability of the vaccine four weeks after the third injection

About 18 participants will be given two doses of PLX cells or placebo on a randomized, double-blind basis

In 2008 and 2009, 20 patients suffering from moderate to severe allergies to birch pollen were enrolled in a double-blind, randomized, placebo-controlled Phase I/IIa trial and received five subcutaneous injections over two months of either AllerT (N = 15) or placebo (N = 5

The submission was based on the results of clinical studies in more than 3,000 pregnant women at term including the Expedite study, a Phase III, double-blind, randomized, multicenter study of 1,358 patients at 35 U.S

The submission was based on the results of clinical studies in more than 3,000 pregnant women at term including the Expedite study, a Phase III, double-blind, randomized, multicenter study of 1,358 patients at 35 U.S